New automated chemiluminescent assay for erythropoietin

Benson, Elizabeth W.; Hardy, Robert W.; Chaffin, Carolyn; Robinson, C. Andrew; Konrad, Robert J.

doi:10.1002/1098-2825(20001212)14:6<271::aid-jcla4>3.0.co;2-8

Cited by 33 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma erythropoietin levels were measured with the IMMULITE EPO assay (Diagnostic Products Corp, Los Angeles, Calif), which was described previously. 10 This assay consists of a ligand-labeled monoclonal anti-erythropoietin capture antibody, an alkaline phosphatase-labeled polyclonal conjugate antibody, and solid-phase anti-ligand-coated polystyrene beads. The amount of plasma erythropoietin was quantified by chemiluminescent measurement in a luminometer.…”

Section: Erythropoietin Measurementsmentioning

confidence: 99%

Endogenous Erythropoietin and Outcome in Heart Failure

et al. 2010

View full text Add to dashboard Cite

Background-Endogenous erythropoietin is increased in patients with heart failure (HF). Previous small-scale data suggest that these erythropoietin levels are related to prognosis. This study aims to analyze the clinical and prognostic value of erythropoietin levels in relation to hemoglobin in a large cohort of HF patients. Methods and Results-In patients hospitalized for HF, endogenous erythropoietin levels were measured at discharge and after 6 months. In anemic patients, the relation between erythropoietin and hemoglobin levels was determined by calculating the observed/predicted ratio of erythropoietin levels. We studied data from 605 patients with HF. Mean age was 71Ϯ11 years; 62% were male; and mean left ventricular ejection fraction was 0.33Ϯ0.14. Median erythropoietin levels were 9.6 U/L at baseline and 10.5 U/L at 6 months. Higher erythropoietin levels at baseline were independently related to an increased mortality at 18 months (hazard ratio, 2.06; 95% confidence interval, 1.40 to 3.04; PϽ0.01). In addition, persistently elevated erythropoietin levels (higher than median at baseline and at 6 months) were related to an increased mortality risk (hazard ratio, 2.24; 95% confidence interval, 1.02 to 4.90; Pϭ0.044). The observed/predicted ratio was determined in a subset of anemic patients, 79% of whom had erythropoietin levels lower than expected and 9% had levels higher than expected on the basis of their hemoglobin. Multivariate Cox regression analysis revealed that a higher observed/predicted ratio was related to an increased mortality risk (hazard ratio, 3.52; 95% confidence interval, 1.53 to 8.12; Pϭ0.003). Conclusions-Erythropoietin levels predict mortality in HF patients, and persistently elevated levels have an independent prognostic value. In anemic HF patients, the majority had a low observed/predicted ratio. However, a higher observed/predicted ratio may be related to an independent increased mortality risk. (Circulation. 2010;121:245-251.)

show abstract

Section: Erythropoietin Measurementsmentioning

confidence: 99%

Endogenous Erythropoietin and Outcome in Heart Failure

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A standard CK and CK-MB monitoring was completed in all patients. Serum EPO levels were measured at baseline, after 4, 24 and 72 h and 10 and 30-days after PCI, using IM-MULITE EPO assay (DPC, Los Angeles, CA, USA), as described before [15,16].…”

Section: Clinical Parametersmentioning

confidence: 99%

A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

Lipšic

Meer

Voors

et al. 2006

Cardiovasc Drugs Ther

177

115

View full text Add to dashboard Cite

Aims: Besides stimulating hematopoiesis, erythropoietin (EPO) protects against experimental ischemic injury in the heart. The present study evaluated the safety and tolerability of EPO treatment in non-anemic patients with acute myocardial infarction (MI).Methods and Results: In this single-center, investigatorinitiated, prospective study, patients with a first acute MI were randomized to one bolus of 300 µg darbepoetin alfa or no additional medication before primary coronary intervention. Twenty-two patients (mean age 59 ± 2 years) were included. In the darbepoetin group, serum EPO-levels increased to 130-270 times that of controls, within the first 24 h. After darbepoetin administration, only small and nonsignificant changes in hematocrit levels were observed, while endothelial progenitor cells (EPCs, CD34 + /CD45−) were increased at 72 h (2.8 vs. 1.0 cells/µl in control group, p < 0.01). No adverse events were recorded during the 30-day follow-up. After 4 months, left ventricular ejection fraction was similar in the two groups (52 ± 3% in darbepoetin vs. 48 ± 5% in control group, p = NS).Conclusions: Intravenous single high-dose darbepoetin alfa in acute MI is both safe and well tolerated. Darbepoetin treatment after MI stimulates EPCs mobilization. The results of this first pilot study support a larger scale clinical trial to establish efficacy of EPO administration in patients after acute MI.

show abstract

“…The sTfr concentrations were determined by an automated immunonephelometric assay (Dade Behring GmbH). The performance characteristics of the serum EPO and sTfr assays have been described (11,12 ).…”

Section: Protocolmentioning

confidence: 99%

Detection of Recombinant Human Erythropoietin in Urine by Isoelectric Focusing

Andreas¹,

Catlin

Green³

et al. 2003

Clinical Chemistry

View full text Add to dashboard Cite

Background: Doping with erythropoietic proteins such as recombinant human erythropoietin (rHuEPO) and darbepoetin alfa is a serious issue in sport. There is little information on the time course of detection of rHuEPO in urine and on methods to evaluate electrophoresisbased data. Methods: We used a recently described isoelectric focusing method for detecting rHuEPO and endogenous EPO in urine obtained from individuals treated with placebo or epoetin alfa. The latter was administered subcutaneously at 50 IU/kg on days 0, 2, 4, 7, 9, 11, 14, 16, and 18. Blood and urine samples were collected during the morning of study days ؊3, 0, 2, 4, 7, 9, 11, 14, 16, and 18 and on days 2, 3, 4, and 7 postadministration. We developed visual and numerical (two-band ratio) techniques to evaluate the electropherograms for the presence of rHuEPO. Results: Compared with the placebo group, the epoetin alfa-treated group responded with increases in hematocrit, reticulocytes, macrocytes, serum EPO, and serum soluble transferrin receptor. The electropherograms showed that the pattern of bands arising from urinary rHuEPO is different from that of endogenous urinary EPO. Both the two-band ratio and the visual technique detected rHuEPO in all 14 epoetin alfa-treated individuals 3 days after the last dose. On the 7th day after the last dose, both techniques detected rHuEPO in approximately one-half of the participants. rHuEPO was not detected in the placebo-treated individuals. Conclusions: The isoelectric focusing method detects rHuEPO in most urine samples collected 3 days after nine doses of epoetin alfa. The numerical two-band

show abstract

New automated chemiluminescent assay for erythropoietin

Cited by 33 publications

References 8 publications

Endogenous Erythropoietin and Outcome in Heart Failure

Endogenous Erythropoietin and Outcome in Heart Failure

A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

Detection of Recombinant Human Erythropoietin in Urine by Isoelectric Focusing

Contact Info

Product

Resources

About